Genmab AS 2024 AR2
The report highlights Genmab's strategic progress in 2024, including the acquisition of ProfoundBio, which expanded its pipeline with late-stage assets like Rina-S. Financially, the company achieved a revenue of DKK 21,526 million, driven by strong royalty growth from DARZALEX and Kesimpta. On the sustainability front, Genmab completed its first double materiality assessment in accordance with the CSRD and integrated its sustainability statements into the annual report. Additionally, the company set its first long-term emission reduction targets for Scope 1 and 2 emissions and achieved 77% renewable electricity across all sites.
Company: Genmab AS
Sector: Health Care
Country: Denmark
Year: 2024
Type: AR2
Pages: 205
Genmab AS
Annual Report
The report highlights Genmab's strategic progress in 2024, including the acquisition of ProfoundBio, which expanded its pipeline with late-stage assets like Rina-S. Financially, the company achieved a revenue of DKK 21,526 million, driven by strong royalty growth from DARZALEX and Kesimpta. On the sustainability front, Genmab completed its first double materiality assessment in accordance with the CSRD and integrated its sustainability statements into the annual report. Additionally, the company set its first long-term emission reduction targets for Scope 1 and 2 emissions and achieved 77% renewable electricity across all sites.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Employees